Clinical Trials Sponsored by TuBerculosis Vaccine Initiative

Total 107 results

Biofabri, S.L
South African Tuberculosis Vaccine Initiative; TuBerculosis Vaccine Initiative and other collaborators

Completed

Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates (MTBVAC-03)

Tuberculosis

South Africa
IDRI
South African Tuberculosis Vaccine Initiative; Aeras

Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

Pulmonary Tuberculosis

South Africa
IDRI
Wellcome Trust; South African Tuberculosis Vaccine Initiative

Completed

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

Pulmonary Tuberculosis

South Africa
International AIDS Vaccine Initiative
Biofabri, S.L; South African Tuberculosis Vaccine Initiative; Universidad de...

Completed

MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa (A-050)

Tuberculosis

South Africa
Biofabri, S.L
South African Tuberculosis Vaccine Initiative; TuBerculosis Vaccine Initiative and other collaborators

Completed

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults (MTBVAC-Ph1b)

Tuberculosis

South Africa
International AIDS Vaccine Initiative

Completed

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

HIV/AIDS

United States
European Malaria Vaccine Initiative

Unknown

GMZ2-Aluminum Hydroxide Phase I, Tübingen

Malaria

Germany
International AIDS Vaccine Initiative

Completed

Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine

HIV Infections

United Kingdom
International AIDS Vaccine Initiative

Completed

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

HIV Infection

Uganda
International AIDS Vaccine Initiative

Completed

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

HIV Infections

Kenya
International AIDS Vaccine Initiative

Completed

Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers

HIV Infections

United Kingdom, Kenya, Rwanda
Biofabri, S.L
Centre Hospitalier Universitaire Vaudois; TuBerculosis Vaccine Initiative; Universidad...

Completed

Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine. (MTBVAC)

Healthy | Tuberculosis

Switzerland
International AIDS Vaccine Initiative
Auro Vaccines LLC; Ichor Medical Systems Incorporated

Completed

Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers

HIV Infections

Rwanda, Uganda, Kenya
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
HIV Vaccine Trials Network
South Africa AIDS Vaccine Initiative

Completed

Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults

HIV Seronegativity | HIV Preventive Vaccine

South Africa
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Recruiting

Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa

Malaria | Malaria Vaccines

Burkina Faso, Ghana, Kenya, Malawi, Senegal, Tanzania
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

Malaria

Ghana, Kenya, Mozambique, Tanzania, Burkina Faso, Gabon, Malawi
International AIDS Vaccine Initiative
Targeted Genetics Corporation

Completed

Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid (TGC14F)

HIV Infections | Human Immunodeficiency Virus Infections

Uganda, South Africa, Zambia
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

Malaria

Malawi
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Epidemiology Study of Malaria Transmission Intensity in Africa

Malaria | Malaria Vaccines

Ghana, Tanzania, Gabon, Kenya, Burkina Faso, Malawi
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children

Malaria

Nigeria
CMV Research Foundation
International AIDS Vaccine Initiative

Completed

Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age

Cytomegalovirus

United States
International AIDS Vaccine Initiative
University of Rochester

Completed

A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers

HIV Infections | HIV

United States
Sanaria Inc.
The PATH Malaria Vaccine Initiative (MVI)

Completed

Clinical Trial of the PfSPZ Vaccine

Plasmodium Falciparum

United States
Statens Serum Institut
Bill and Melinda Gates Foundation; Aurum Institute; Leiden University Medical... and other collaborators

Recruiting

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b (nTB-01)

Healthy

South Africa
European Malaria Vaccine Initiative
University of Oxford; Wellcome Trust

Completed

Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

Malaria | Malaria, Falciparum

United Kingdom
International AIDS Vaccine Initiative
Universidad de Zaragoza; Biofabri, SLU

Not yet recruiting

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.

Tuberculosis (TB)
Groupe de Recherche Action en Sante
European Vaccine Initiative

Recruiting

Malaria Burden in Pregnant Women and the Incidence of Pregnancy in a Cohort of Nulligravida (EPI-PAM)

Maternal Malaria During Pregnancy - Baby Not Yet Delivered

Burkina Faso
International AIDS Vaccine Initiative
Coalition for Epidemic Preparedness Innovations

Recruiting

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Lassa Fever

Ghana, Liberia, Nigeria
Biomedical Research Center EPLS
University of Cape Town; Biofabri, S.L; TuBerculosis Vaccine Initiative; Universidad... and other collaborators

Completed

Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal (MTBVAC-EPI)

Tuberculosis

France
Radboud University Medical Center
The PATH Malaria Vaccine Initiative (MVI)

Terminated

Safety and Efficacy of NF135 CPS Immunization (CPS135)

Malaria,Falciparum | Controlled Human Malaria Infection | Immunization; Infection

Netherlands
International AIDS Vaccine Initiative
Biomedical Advanced Research and Development Authority

Active, not recruiting

Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

Ebola Sudan Virus Disease

United States
Radboud University Medical Center
The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F (TB31F)

Malaria,Falciparum

Netherlands
GlaxoSmithKline
Crucell Holland BV; The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Malaria

United States
International AIDS Vaccine Initiative
Massachusetts General Hospital; GlaxoSmithKline; Fred Hutchinson Cancer Research... and other collaborators

Completed

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

HIV Infections

United States, Kenya
International AIDS Vaccine Initiative
University of Nairobi; Medical Research Council-Oxford

Completed

A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers

HIV Infections

United Kingdom, Kenya
Seattle Children's Research Institute (SCRI)
The PATH Malaria Vaccine Initiative (MVI)

Completed

Reproducibility of Malaria Challenge in Healthy Volunteers

Healthy

United States
MRC/UVRI and LSHTM Uganda Research Unit
International AIDS Vaccine Initiative

Recruiting

Feasibility of Identifying, Enrolling and Following Acute and Early HIV-1 Infected Individuals. (KILGORIS)

Acute Human Immunodeficiency Virus Type I Infection

Uganda
Emory University
International AIDS Vaccine Initiative; Zambia-Emory HIV Research Project

Completed

Zambia SiVET MMR Tdap-IPV (SiVET)

High Risk for HIV

Zambia
Johns Hopkins University
Aurum Institute; KNCV Tuberculosis Foundation; Clinton Health Access Initiative...

Completed

Choice Architecture Based TB Preventive Therapy Prescribing (CAT)

HIV/AIDS | Tuberculosis

Malawi, Mozambique, Zimbabwe
International AIDS Vaccine Initiative
Beth Israel Deaconess Medical Center; University of Rochester

Completed

Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine

HIV

United States
International AIDS Vaccine Initiative
University of Rochester; Aaron Diamond AIDS Research Center

Completed

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...
International AIDS Vaccine Initiative

Withdrawn

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

HIV Infections
International AIDS Vaccine Initiative
University of Rochester; Aaron Diamond AIDS Research Center

Completed

Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults (C001)

HIV Infection

United States
International AIDS Vaccine Initiative
University of Cape Town Lung Institute; European and Developing Countries Clinical... and other collaborators

Active, not recruiting

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Tuberculosis, Pulmonary

South Africa, Tanzania
U.S. Army Medical Research and Development Command
The PATH Malaria Vaccine Initiative (MVI)

Withdrawn

A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents (AdBa)

Healthy | Malaria

United States
Aeras
Oslo University Hospital; University of Copenhagen; University of Bergen; Aurum... and other collaborators

Withdrawn

A Phase II Study of H56:IC31 in Healthy Adolescents (A-043)

Tuberculosis Infection

South Africa, Tanzania
European Vaccine Initiative
University of Oxford; Malaria Research and Training Center, Bamako, Mali

Not yet recruiting

Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali

Healthy Women of Child Bearing Potential
International AIDS Vaccine Initiative
GlaxoSmithKline; George Washington University; Amsterdam UMC, location VUmc; Rockefeller...

Active, not recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

HIV Infections

United States, Netherlands

Clinical Trials Sponsored by TuBerculosis Vaccine Initiative

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations